Dr. Davis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1301 Medical Center Dr
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-936-0605
Summary
- Dr. Elizabeth Davis is an oncologist in Nashville, TN and is affiliated with Vanderbilt University. She has been in practice for 10 years and specializes in the treatment of patients with bone and soft tissue sarcoma.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2012 - 2015- University of MichiganResidency, Internal Medicine, 2009 - 2012
Wright State University Boonshoft School of MedicineClass of 2009
Duke UniversityBS, Biology, 2004
Certifications & Licensure
TN State Medical License 2016 - 2026
AL State Medical License 2020 - 2020
MI State Medical License 2015 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Localized Leiomyosarcoma Biomarker Protocol Start of enrollment: 2023 Apr 26
- 9-ING-41 in Patients With Advanced Cancers Start of enrollment: 2019 Jan 04
Roles: Contact
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue Start of enrollment: 2021 Sep 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 30 citationsFirst-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden
Journal for Immunotherapy of Cancer. 2022-10-01 - 22 citationsAtezolizumab for Advanced Alveolar Soft Part Sarcoma.Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, Nancy Moore, Jared C Foster
The New England Journal of Medicine. 2023-09-07 - 127 citationsChronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ. Randall Patrinely, Rebecca N. Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers
JAMA Oncology. 2021-05-01
Professional Memberships
- Member
- Connective Tissue Oncology SocietyMember
- Sarcoma Alliance for Research through CollaborationMember
- Member
- Children's Oncology GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
